Browsing by Subject "MASK"

Sort by: Order: Results:

Now showing items 1-14 of 14
  • Bousquet, Jean; Anto, Josep M.; Bachert, Claus; Haahtela, Tari; Zuberbier, Torsten; Czarlewski, Wienczyslawa; Bedbrook, Anna; Bosnic-Anticevich, Sinthia; Walter Canonica, G.; Cardona, Victoria; Costa, Elisio; Cruz, Alvaro A.; Erhola, Marina; Fokkens, Wytske J.; Fonseca, Joao A.; Illario, Maddalena; Ivancevich, Juan-Carlos; Jutel, Marek; Klimek, Ludger; Kuna, Piotr; Kvedariene, Violeta; Le, L. T. T.; Larenas-Linnemann, Desiree E.; Laune, Daniel; Lourenco, Olga M.; Melen, Erik; Mullol, Joaquim; Niedoszytko, Marek; Odemyr, Mikaela; Okamoto, Yoshitaka; Papadopoulos, Nikos G.; Patella, Vincenzo; Pfaar, Oliver; Pham-Thi, Nhan; Rolland, Christine; Samolinski, Boleslaw; Sheikh, Aziz; Sofiev, Mikhail; Suppli Ulrik, Charlotte; Todo-Bom, Ana; Tomazic, Peter-Valentin; Toppila-Salmi, Sanna; Tsiligianni, Ioanna; Valiulis, Arunas; Valovirta, Erkka; Ventura, Maria-Teresa; Walker, Samantha; Williams, Sian; Yorgancioglu, Arzu; Agache, Ioana; Akdis, Cezmi A.; Almeida, Rute; Ansotegui, Ignacio J.; Annesi-Maesano, Isabella; Arnavielhe, Sylvie; Basagana, Xavier; D. Bateman, Eric; Bedard, Annabelle; Bedolla-Barajas, Martin; Becker, Sven; Bennoor, Kazi S.; Benveniste, Samuel; Bergmann, Karl C.; Bewick, Michael; Bialek, Slawomir; E. Billo, Nils; Bindslev-Jensen, Carsten; Bjermer, Leif; Blain, Hubert; Bonini, Matteo; Bonniaud, Philippe; Bosse, Isabelle; Bouchard, Jacques; Boulet, Louis-Philippe; Bourret, Rodolphe; Boussery, Koen; Braido, Fluvio; Briedis, Vitalis; Briggs, Andrew; Brightling, Christopher E.; Brozek, Jan; Brusselle, Guy; Brussino, Luisa; Buhl, Roland; Buonaiuto, Roland; Calderon, Moises A.; Camargos, Paulo; Camuzat, Thierry; Caraballo, Luis; Carriazo, Ana-Maria; Carr, Warner; Cartier, Christine; Casale, Thomas; Cecchi, Lorenzo; Cepeda Sarabia, Alfonso M.; H. Chavannes, Niels; Chkhartishvili, Ekaterine; Chu, Derek K.; Cingi, Cemal; Correia de Sousa, Jaime; Costa, David J.; Courbis, Anne-Lise; Custovic, Adnan; Cvetkosvki, Biljana; D'Amato, Gennaro; da Silva, Jane; Dantas, Carina; Dokic, Dejan; Dauvilliers, Yves; De Feo, Giulia; De Vries, Govert; Devillier, Philippe; Di Capua, Stefania; Dray, Gerard; Dubakiene, Ruta; Durham, Stephen R.; Dykewicz, Marc; Ebisawa, Motohiro; Gaga, Mina; El-Gamal, Yehia; Heffler, Enrico; Emuzyte, Regina; Farrell, John; Fauquert, Jean-Luc; Fiocchi, Alessandro; Fink-Wagner, Antje; Fontaine, Jean-Francois; Fuentes Perez, Jose M.; Gemicioglu, Bilun; Gamkrelidze, Amiran; Garcia-Aymerich, Judith; Gevaert, Philippe; Gomez, Rene Maximiliano; Gonzalez Diaz, Sandra; Gotua, Maia; Guldemond, Nick A.; Guzman, Maria-Antonieta; Hajjam, Jawad; Huerta Villalobos, Yunuen R.; Humbert, Marc; Iaccarino, Guido; Ierodiakonou, Despo; Iinuma, Tomohisa; Jassem, Ewa; Joos, Guy; Jung, Ki-Suck; Kaidashev, Igor; Kalayci, Omer; Kardas, Przemyslaw; Keil, Thomas; Khaitov, Musa; Khaltaev, Nikolai; Kleine-Tebbe, Jorg; Kouznetsov, Rostislav; Kowalski, Marek L.; Kritikos, Vicky; Kull, Inger; La Grutta, Stefania; Leonardini, Lisa; Ljungberg, Henrik; Lieberman, Philip; Lipworth, Brian; Lodrup Carlsen, Karin C.; Lopes-Pereira, Catarina; Loureiro, Claudia C.; Louis, Renaud; Mair, Alpana; Mahboub, Bassam; Makris, Michael; Malva, Joao; Manning, Patrick; Marshall, Gailen D.; Masjedi, Mohamed R.; Maspero, Jorge F.; Carreiro-Martins, Pedro; Makela, Mika; Mathieu-Dupas, Eve; Maurer, Marcus; De Manuel Keenoy, Esteban; Melo-Gomes, Elisabete; Meltzer, Eli O.; Menditto, Enrica; Mercier, Jacques; Micheli, Yann; Miculinic, Neven; Mihaltan, Florin; Milenkovic, Branislava; Mitsias, Dimitirios I.; Moda, Giuliana; Mogica-Martinez, Maria-Dolores; Mohammad, Yousser; Montefort, Steve; Monti, Ricardo; Morais-Almeida, Mario; Mosges, Ralph; Munter, Lars; Muraro, Antonella; Murray, Ruth; Naclerio, Robert; Napoli, Luigi; Namazova-Baranova, Leyla; Neffen, Hugo; Nekam, Kristoff; Neou, Angelo; Nordlund, Bjorn; Novellino, Ettore; Nyembue, Dieudonne; O'Hehir, Robyn; Ohta, Ken; Okubo, Kimi; Onorato, Gabrielle L.; Orlando, Valentina; Ouedraogo, Solange; Palamarchuk, Julia; Pali-Scholl, Isabella; Panzner, Peter; Park, Hae-Sim; Passalacqua, Gianni; Pepin, Jean-Louis; Paulino, Ema; Pawankar, Ruby; Phillips, Jim; Picard, Robert; Pinnock, Hilary; Plavec, Davor; Popov, Todor A.; Portejoie, Fabienne; Price, David; Prokopakis, Emmanuel P.; Psarros, Fotis; Pugin, Benoit; Puggioni, Francesca; Quinones-Delgado, Pablo; Raciborski, Filip; Rajabian-Soderlund, Rojin; Regateiro, Frederico S.; Reitsma, Sietze; Rivero-Yeverino, Daniela; Roberts, Graham; Roche, Nicolas; Rodriguez-Zagal, Erendira; Rolland, Christine; Roller-Wirnsberger, Regina E.; Rosario, Nelson; Romano, Antonino; Rottem, Menachem; Ryan, Dermot; Salimaki, Johanna; Sanchez-Borges, Mario M.; Sastre, Joaquin; Scadding, Glenis K.; Scheire, Sophie; Schmid-Grendelmeier, Peter; Schunemann, Holger J.; Sarquis Serpa, Faradiba; Shamji, Mohamed; Sisul, Juan-Carlos; Sofiev, Mikhail; Sole, Dirceu; Somekh, David; Sooronbaev, Talant; Sova, Milan; Spertini, F.; Spranger, Otto; Stellato, Cristiana; Stelmach, Rafael; Thibaudon, Michel; To, Teresa; Toumi, Mondher; Usmani, Omar; Valero, Antonio A.; Valenta, Rudolph; Valentin-Rostan, Marylin; Pereira, Marilyn Urrutia; van der Kleij, Rianne; Van Eerd, Michiel; Vandenplas, Olivier; Vasankari, Tuula; Vaz Carneiro, Antonio; Vezzani, Giorgio; Viart, Frederic; Viegi, Giovanni; Wallace, Dana; Wagenmann, Martin; Wang, De Yun; Waserman, Susan; Wickman, Magnus; Williams, Dennis M.; Wong, Gary; Wroczynski, Piotr; Yiallouros, Panayiotis K.; Yusuf, Osman M.; Zar, Heather J.; Zeng, Stephane; Zernotti, Mario E.; Zhang, Luo; Shan Zhong, Nan; Zidarn, Mihaela (2021)
    Digital anamorphosis is used to define a distorted image of health and care that may be viewed correctly using digital tools and strategies. MASK digital anamorphosis represents the process used by MASK to develop the digital transformation of health and care in rhinitis. It strengthens the ARIA change management strategy in the prevention and management of airway disease. The MASK strategy is based on validated digital tools. Using the MASK digital tool and the CARAT online enhanced clinical framework, solutions for practical steps of digital enhancement of care are proposed.
  • Bousquet, J.; Onorato, G. L.; Bachert, C.; Barbolini, M.; Bedbrook, A.; Bjermer, L.; de Sousa, J. Correia; Chavannes, N. H.; Cruz, A. A.; Keenoy, E. De Manuel; Devillier, P.; Fonseca, J.; Hun, S.; Kostka, T.; Hellings, P. W.; Illario, M.; Ivancevich, J. C.; Larenas-Linnemann, D.; Millot-Keurinck, J.; Ryan, D.; Samolinski, B.; Sheikh, A.; Yorgancioglu, A.; Agache, I.; Arnavielhe, S.; Bewick, M.; Annesi-Maesano, I.; Anto, J. M.; Bergmann, K. C.; Bindslev-Jensen, C.; Bosnic-Anticevich, S.; Bouchard, J.; Caimmi, D. P.; Camargos, P.; Canonica, G. W.; Cardona, V.; Carriazo, A. M.; Cingi, C.; Colgan, E.; Custovic, A.; Dahl, R.; Demoly, P.; De Vries, G.; Fokkens, W. J.; Fontaine, J. F.; Gemicioglu, B.; Guldemond, N.; Gutter, Z.; Haahtela, T.; Hellqvist-Dahl, B.; Jares, E.; Joos, G.; Just, J.; Khaltaev, N.; Keil, T.; Klimek, L.; Kowalski, M. L.; Kull, I.; Kuna, P.; Kvedariene, V.; Laune, D.; Louis, R.; Magnan, A.; Malva, J.; Mathieu-Dupas, E.; Melen, E.; Menditto, E.; Morais-Almeida, M.; Mosges, R.; Mullol, J.; Murray, R.; Neffen, H.; O'Hehir, R.; Palkonen, S.; Papadopoulos, N. G.; Passalacqua, G.; Pepin, J. L.; Portejoie, F.; Price, D.; Pugin, B.; Raciborski, F.; Simons, F. E. R.; Sova, M.; Spranger, O.; Stellato, C.; Bom, A. Todo; Tomazic, P. V.; Triggiani, M.; Valero, A.; Valovirta, E.; VandenPlas, O.; Valiulis, A.; Van Eerd, M.; Ventura, M. T.; Wickman, M.; Young, I.; Zuberbier, T.; Zurkuhlen, A.; Senn, A. (2017)
    A Good Practice is a practice that works well, produces good results, and is recommended as a model. MACVIA-ARIA Sentinel Network (MASK), the new Allergic Rhinitis and its Impact on Asthma (ARIA) initiative, is an example of a Good Practice focusing on the implementation of multi-sectoral care pathways using emerging technologies with real life data in rhinitis and asthma multi-morbidity. The European Union Joint Action on Chronic Diseases and Promoting Healthy Ageing across the Life Cycle (JA-CHRODIS) has developed a checklist of 28 items for the evaluation of Good Practices. SUNFRAIL (Reference Sites Network for Prevention and Care of Frailty and Chronic Conditions in community dwelling persons of EU Countries), a European Union project, assessed whether MASK is in line with the 28 items of JA-CHRODIS. A short summary was proposed for each item and 18 experts, all members of ARIA and SUNFRAIL from 12 countries, assessed the 28 items using a Survey Monkey-based questionnaire. A visual analogue scale (VAS) from 0 (strongly disagree) to 100 (strongly agree) was used. Agreement equal or over 75% was observed for 14 items (50%). MASK is following the JA-CHRODIS recommendations for the evaluation of Good Practices.
  • MASK Study GroupJr; Bedard, Annabelle; Anto, Josep M.; Fonseca, Joao A.; Toppila-Salmi, Sanna; Basagana, Xavier (2020)
    Background In allergic rhinitis, a relevant outcome providing information on the effectiveness of interventions is needed. In MASK-air (Mobile Airways Sentinel Network), a visual analogue scale (VAS) for work is used as a relevant outcome. This study aimed to assess the performance of the work VAS work by comparing VAS work with other VAS measurements and symptom-medication scores obtained concurrently. Methods All consecutive MASK-air users in 23 countries from 1 June 2016 to 31 October 2018 were included (14 189 users; 205 904 days). Geolocalized users self-assessed daily symptom control using the touchscreen functionality on their smart phone to click on VAS scores (ranging from 0 to 100) for overall symptoms (global), nose, eyes, asthma and work. Two symptom-medication scores were used: the modified EAACI CSMS score and the MASK control score for rhinitis. To assess data quality, the intra-individual response variability (IRV) index was calculated. Results A strong correlation was observed between VAS work and other VAS. The highest levels for correlation with VAS work and variance explained in VAS work were found with VAS global, followed by VAS nose, eye and asthma. In comparison with VAS global, the mCSMS and MASK control score showed a lower correlation with VAS work. Results are unlikely to be explained by a low quality of data arising from repeated VAS measures. Conclusions VAS work correlates with other outcomes (VAS global, nose, eye and asthma) but less well with a symptom-medication score. VAS work should be considered as a potentially useful AR outcome in intervention studies.
  • Rontu, Ville; Nolvi, Anton; Hokkanen, Ari; Haeggström, Edward; Kassamakov, Ivan; Franssila, Sami (2018)
    We have investigated elastic and fracture properties of amorphous Al2O3 thin films deposited by atomic layer deposition (ALD) with bulge test technique using a free-standing thin film membrane and extended applicability of bulge test technique. Elastic modulus was determined to be 115 GPa for a 50 nm thick film and 170 GPa for a 15 nm thick film. Residual stress was 142 MPa in the 50 nm Al2O3 film while it was 116 MPa in the 15 nm Al2O3 film. Density was 3.11 g cm(-3) for the 50 nm film and 3.28 g cm(-3) for the 15 nm film. Fracture strength at 100 hPa s(-1) pressure ramp rate was 1.72 GPa for the 50 nm film while for the 15 nm film it was 4.21 GPa, almost 2.5-fold. Fracture strength was observed to be positively strain-rate dependent. Weibull moduli of these films were very high being around 50. The effective volume of a circular film in bulge test was determined from a FEM model enabling future comparison of fracture strength data between different techniques.
  • MASK Study Grp (2018)
    Background: Collecting data on the localization of users is a key issue for the MASK (Mobile Airways Sentinel network: the Allergy Diary) App. Data anonymization is a method of sanitization for privacy. The European Commission's Article 29 Working Party stated that geolocation information is personal data. To assess geolocation using the MASK method and to compare two anonymization methods in the MASK database to find an optimal privacy method. Methods: Geolocation was studied for all people who used the Allergy Diary App from December 2015 to November 2017 and who reported medical outcomes. Two different anonymization methods have been evaluated: Noise addition (randomization) and k-anonymity (generalization). Results: Ninety-three thousand one hundred and sixteen days of VAS were collected from 8535 users and 54,500 (58. 5%) were geolocalized, corresponding to 5428 users. Noise addition was found to be less accurate than k-anonymity using MASK data to protect the users' life privacy. Discussion: k-anonymity is an acceptable method for the anonymization of MASK data and results can be used for other databases.
  • MASK Study Grp; Bousquet, J.; Bedbrook, A.; Czarlewski, W.; Haahtela, T.; Valovirta, E.; Vasankari, T.; Toppila-Salmi, S.; Salimäki, Johanna; Kuitunen, M.; Wallace, D. V. (2019)
    AimsMobile Airways Sentinel NetworK (MASK) belongs to the Fondation Partenariale MACVIA-LR of Montpellier, France and aims to provide an active and healthy life to rhinitis sufferers and to those with asthma multimorbidity across the life cycle, whatever their gender or socio-economic status, in order to reduce health and social inequities incurred by the disease and to improve the digital transformation of health and care. The ultimate goal is to change the management strategy in chronic diseases.MethodsMASK implements ICT technologies for individualized and predictive medicine to develop novel care pathways by a multi-disciplinary group centred around the patients.StakeholdersInclude patients, health care professionals (pharmacists and physicians), authorities, patient's associations, private and public sectors.ResultsMASK is deployed in 23 countries and 17 languages. 26,000 users have registered.EU grants (2018)MASK is participating in EU projects (POLLAR: impact of air POLLution in Asthma and Rhinitis, EIT Health, DigitalHealthEurope, Euriphi and Vigour).Lessons learnt(i) Adherence to treatment is the major problem of allergic disease, (ii) Self-management strategies should be considerably expanded (behavioural), (iii) Change management is essential in allergic diseases, (iv) Education strategies should be reconsidered using a patient-centred approach and (v) Lessons learnt for allergic diseases can be expanded to chronic diseases.
  • Bousquet, J.; Bedbrook, A.; Czarlewski, W.; Onorato, G. L; Arnavielhe, S.; Laune, D.; Mathieu-Dupas, E.; Fonseca, J.; Costa, E.; Lourenço, O.; Morais-Almeida, M.; Todo-Bom, A.; Illario, M.; Menditto, E.; Canonica, G. W; Cecchi, L.; Monti, R.; Napoli, L.; Ventura, M. T; De Feo, G.; Fokkens, W. J; Chavannes, N. H; Reitsma, S.; Cruz, A. A; da Silva, J.; Serpa, F. S; Larenas-Linnemann, D.; Fuentes Perez, J. M; Huerta-Villalobos, Y. R; Rivero-Yeverino, D.; Rodriguez-Zagal, E.; Valiulis, A.; Dubakiene, R.; Emuzyte, R.; Kvedariene, V.; Annesi-Maesano, I.; Blain, H.; Bonniaud, P.; Bosse, I.; Dauvilliers, Y.; Devillier, P.; Fontaine, J. F; Pépin, J. L; Pham-Thi, N.; Portejoie, F.; Picard, R.; Roche, N.; Rolland, C.; Schmidt-Grendelmeier, P.; Kuna, P.; Samolinski, B.; Anto, J. M; Cardona, V.; Mullol, J.; Pinnock, H.; Ryan, D.; Sheikh, A.; Walker, S.; Williams, S.; Becker, S.; Klimek, L.; Pfaar, O.; Bergmann, K. C; Mösges, R.; Zuberbier, T.; Roller-Wirnsberger, R. E; Tomazic, P. V; Haahtela, T.; Salimäki, J.; Toppila-Salmi, S.; Valovirta, E.; Vasankari, T.; Gemicioğlu, B.; Yorgancioglu, A.; Papadopoulos, N. G; Prokopakis, E. P; Tsiligianni, I. G; Bosnic-Anticevich, S.; O’Hehir, R.; Ivancevich, J. C; Neffen, H.; Zernotti, M. E; Kull, I.; Melén, E.; Wickman, M.; Bachert, C.; Hellings, P. W; Brusselle, G.; Palkonen, S.; Bindslev-Jensen, C.; Eller, E.; Waserman, S.; Boulet, L. P; Bouchard, J.; Chu, D. K; Schünemann, H. J; Sova, M.; De Vries, G.; van Eerd, M.; Agache, I.; Ansotegui, I. J; Bewick, M.; Casale, T.; Dykewick, M.; Ebisawa, M.; Murray, R.; Naclerio, R.; Okamoto, Y.; Wallace, D. V (BioMed Central, 2019)
    Abstract Aims Mobile Airways Sentinel NetworK (MASK) belongs to the Fondation Partenariale MACVIA-LR of Montpellier, France and aims to provide an active and healthy life to rhinitis sufferers and to those with asthma multimorbidity across the life cycle, whatever their gender or socio-economic status, in order to reduce health and social inequities incurred by the disease and to improve the digital transformation of health and care. The ultimate goal is to change the management strategy in chronic diseases. Methods MASK implements ICT technologies for individualized and predictive medicine to develop novel care pathways by a multi-disciplinary group centred around the patients. Stakeholders Include patients, health care professionals (pharmacists and physicians), authorities, patient’s associations, private and public sectors. Results MASK is deployed in 23 countries and 17 languages. 26,000 users have registered. EU grants (2018) MASK is participating in EU projects (POLLAR: impact of air POLLution in Asthma and Rhinitis, EIT Health, DigitalHealthEurope, Euriphi and Vigour). Lessons learnt (i) Adherence to treatment is the major problem of allergic disease, (ii) Self-management strategies should be considerably expanded (behavioural), (iii) Change management is essential in allergic diseases, (iv) Education strategies should be reconsidered using a patient-centred approach and (v) Lessons learnt for allergic diseases can be expanded to chronic diseases.
  • MASK Study Grp (2018)
    mHealth, such as apps running on consumer smart devices is becoming increasingly popular and has the potential to profoundly affect healthcare and health outcomes. However, it may be disruptive and results achieved are not always reaching the goals. Allergic Rhinitis and its Impact on Asthma (ARIA) has evolved from a guideline using the best evidence-based approach to care pathways suited to real-life using mobile technology in allergic rhinitis (AR) and asthma multimorbidity. Patients largely use over-the-counter medications dispensed in pharmacies. Shared decision making centered around the patient and based on self-management should be the norm. Mobile Airways Sentinel networK (MASK), the Phase 3 ARIA initiative, is based on the freely available MASK app (the Allergy Diary, Android and iOS platforms). MASK is available in 16 languages and deployed in 23 countries. The present paper provides an overview of the methods used in MASK and the key results obtained to date. These include a novel phenotypic characterization of the patients, confirmation of the impact of allergic rhinitis on work productivity and treatment patterns in real life. Most patients appear to self-medicate, are often non-adherent and do not follow guidelines. Moreover, the Allergy Diary is able to distinguish between AR medications. The potential usefulness of MASK will be further explored by POLLAR (Impact of Air Pollution on Asthma and Rhinitis), a new Horizon 2020 project using the Allergy Diary.
  • Bousquet, Jean; Ansotegui, Ignacio J.; Anto, Josep M.; Arnavielhe, Sylvie; Bachert, Claus; Basagana, Xavier; Bedard, Annabelle; Bedbrook, Anna; Bonini, Matteo; Bosnic-Anticevich, Sinthia; Braido, Fulvio; Cardona, Vicky; Czarlewski, Wienczyslawa; Cruz, Alvaro A.; Demoly, Pascal; De Vries, Govert; Dramburg, Stephanie; Mathieu-Dupas, Eve; Erhola, Marina; Fokkens, Wytske J.; Fonseca, Joao A.; Haahtela, Tari; Hellings, Peter W.; Illario, Maddalena; Ivancevich, Juan Carlos; Jormanainen, Vesa; Klimek, Ludger; Kuna, Piotr; Kvedariene, Violeta; Laune, Daniel; Larenas-Linnemann, Desiree; Lourenco, Olga; Onorato, Gabrielle L.; Matricardi, Paolo M.; Melen, Erik; Mullol, Joaquim; Papadopoulos, Nikos G.; Pfaar, Oliver; Nhan Pham-Thi,; Sheikh, Aziz; Tan, Rachel; To, Teresa; Tomazic, Peter Valentin; Toppila-Salmi, Sanna; Tripodi, Salvadore; Wallace, Dana; Valiulis, Arunas; van Eerd, Michiel; Ventura, Maria Teresa; Yorgancioglu, Arzu; Zuberbier, Torsten (2019)
    Smart devices and Internet-based applications (apps) are largely used in allergic rhinitis and may help to address some unmet needs. However, these new tools need to first of all be tested for privacy rules, acceptability, usability, and cost-effectiveness. Second, they should be evaluated in the frame of the digital transformation of health, their impact on health care delivery, and health outcomes. This review (1) summarizes some existing mobile health apps for allergic rhinitis and reviews those in which testing has been published, (2) discusses apps that include risk factors of allergic rhinitis, (3) examines the impact of mobile health apps in phenotype discovery, (4) provides real-world evidence for care pathways, and finally (5) discusses mobile health tools enabling the digital transformation of health and care, empowering citizens, and building a healthier society. (C) 2019 American Academy of Allergy, Asthma & Immunology
  • MASK Study Grp; Bedard, Annabelle; Basagana, Xavier; Anto, Josep M.; Haahtela, Tari; Toppila-Salmi, Sanna (2019)
    Background: Mobile health can be used to generate innovative insights into optimizing treatment to improve allergic rhinitis (AR) control. Objectives: A cross-sectional real-world observational study was undertaken in 22 countries to complement a pilot study and provide novel information on medication use, disease control, and work productivity in the everyday life of patients with AR. Methods: A mobile phone app (Allergy Diary, which is freely available on Google Play and Apple stores) was used to collect the data of daily visual analogue scale (VAS) scores for (1) overall allergic symptoms; (2) nasal, ocular, and asthma symptoms; (3) work; and (4) medication use by using a treatment scroll list including all allergy medications (prescribed and over-the-counter) customized for 22 countries. The 4 most common intranasal medications containing intranasal corticosteroids and 8 oral H-1-antihistamines were studied. Results: Nine thousand one hundred twenty-two users filled in 112,054 days of VASs in 2016 and 2017. Assessment of days was informative. Control of days with rhinitis differed between no (best control), single (good control for intranasal corticosteroid-treated days), or multiple (worst control) treatments. Users with the worst control increased the range of treatments being used. The same trend was found for asthma, eye symptoms, and work productivity. Differences between oral H-1-antihistamines were found. Conclusions: This study confirms the usefulness of the Allergy Diary in accessing and assessing behavior in patients with AR. This observational study using a very simple assessment tool (VAS) on a mobile phone had the potential to answer questions previously thought infeasible.
  • ARIA Study Grp; MASK Study Grp; Bousquet, J. Jean; Schunemann, Holger J.; Togias, Alkis; Haahtela, Tari; Toppila-Salmi, Sanna (2019)
    Background In all societies, the burden and cost of allergic and chronic respiratory diseases are increasing rapidly. Most economies are struggling to deliver modern health care effectively. There is a need to support the transformation of the health care system into integrated care with organizational health literacy. Main body As an example for chronic disease care, MASK (Mobile Airways Sentinel NetworK), a new project of the ARIA (Allergic Rhinitis and its Impact on Asthma) initiative, and POLLAR (Impact of Air POLLution on Asthma and Rhinitis, EIT Health), in collaboration with professional and patient organizations in the field of allergy and airway diseases, are proposing real-life ICPs centred around the patient with rhinitis, and using mHealth to monitor environmental exposure. Three aspects of care pathways are being developed: (i) Patient participation, health literacy and self-care through technology-assisted "patient activation", (ii) Implementation of care pathways by pharmacists and (iii) Next-generation guidelines assessing the recommendations of GRADE guidelines in rhinitis and asthma using real-world evidence (RWE) obtained through mobile technology. The EU and global political agendas are of great importance in supporting the digital transformation of health and care, and MASK has been recognized by DG Sante as a Good Practice in the field of digitally-enabled, integrated, person-centred care. Conclusion In 20 years, ARIA has considerably evolved from the first multimorbidity guideline in respiratory diseases to the digital transformation of health and care with a strong political involvement.
  • Sogacheva, Larisa; Kolmonen, Pekka; Virtanen, Timo H.; Rodriguez, Edith; Saponaro, Giulia; De Leeuw, Gerrit (2017)
    Cloud misclassification is a serious problem in the retrieval of aerosol optical depth (AOD), which might considerably bias the AOD results. On the one hand, residual cloud contamination leads to AOD overestimation, whereas the removal of high-AOD pixels (due to their misclassification as clouds) leads to underestimation. To remove cloudcontaminated areas in AOD retrieved from reflectances measured with the (Advanced) Along Track Scanning Radiometers (ATSR-2 and AATSR), using the ATSR dual-view algorithm (ADV) over land or the ATSR single-view algorithm (ASV) over ocean, a cloud post-processing (CPP) scheme has been developed at the Finnish Meteorological Institute (FMI) as described in Kolmonen et al. (2016). The application of this scheme results in the removal of cloudcontaminated areas, providing spatially smoother AOD maps and favourable comparison with AOD obtained from the ground-based reference measurements from the AERONET sun photometer network. However, closer inspection shows that the CPP also removes areas with elevated AOD not due to cloud contamination, as shown in this paper. We present an improved CPP scheme which better discriminates between cloud-free and cloud-contaminated areas. The CPP thresholds have been further evaluated and adjusted according to the findings. The thresholds for the detection of high-AOD regions (> 60% of the retrieved pixels should be high-AOD (> 0.6) pixels), and cloud contamination criteria for lowAOD regions have been accepted as the default for AOD global post-processing in the improved CPP. Retaining elevated AOD while effectively removing cloud-contaminated pixels affects the resulting global and regional mean AOD values as well as coverage. Effects of the CPP scheme on both spatial and temporal variation for the period 2002-2012 are discussed. With the improved CPP, the AOD coverage increases by 10-15% with respect to the existing scheme. The validation versus AERONET shows an improvement of the correlation coefficient from 0.84 to 0.86 for the global data set for the period 2002-2012. The global aggregated AOD over land for the period 2003-2011 is 0.163 with the improved CPP compared to 0.144 with the existing scheme. The aggregated AOD over ocean and globally (land and ocean together) is 0.164 with the improved CPP scheme (compared to 0.152 and 0.150 with the existing scheme, for ocean and globally respectively). Effects of the improved CPP scheme on the 10-year time series are illustrated and seasonal and temporal changes are discussed. The improved CPP method introduced here is applicable to other aerosol retrieval algorithms. However, the thresholds for detecting the high-AOD regions, which were developed for AATSR, might have to be adjusted to the actual features of the instruments.
  • Bédard, A.; Basagaña, X.; Anto, J. M; Garcia-Aymerich, J.; Devillier, P.; Arnavielhe, S.; Bedbrook, A.; Onorato, G. L; Czarlewski, W.; Murray, R.; Almeida, R.; Fonseca, J. A; Correia da Sousa, J.; Costa, E.; Morais-Almeida, M.; Todo-Bom, A.; Cecchi, L.; De Feo, G.; Illario, M.; Menditto, E.; Monti, R.; Stellato, C.; Ventura, M. T; Annesi-Maesano, I.; Bosse, I.; Fontaine, J. F; Pham-Thi, N.; Thibaudon, M.; Schmid-Grendelmeier, P.; Spertini, F.; Chavannes, N. H; Fokkens, W. J; Reitsma, S.; Dubakiene, R.; Emuzyte, R.; Kvedariene, V.; Valiulis, A.; Kuna, P.; Samolinski, B.; Klimek, L.; Mösges, R.; Pfaar, O.; Shamai, S.; Roller-Wirnsberger, R. E; Tomazic, P. V; Ryan, D.; Sheikh, A.; Haahtela, T.; Toppila-Salmi, S.; Valovirta, E.; Cardona, V.; Mullol, J.; Valero, A.; Makris, M.; Papadopoulos, N. G; Prokopakis, E. P; Psarros, F.; Bachert, C.; Hellings, P. W; Pugin, B.; Bindslev-Jensen, C.; Eller, E.; Kull, I.; Melén, E.; Wickman, M.; De Vries, G.; van Eerd, M.; Agache, I.; Ansotegui, I. J; Bosnic-Anticevich, S.; Cruz, A. A; Casale, T.; Ivancevich, J. C; Larenas-Linnemann, D. E; Sofiev, M.; Wallace, D.; Waserman, S.; Yorgancioglu, A.; Laune, D.; Bousquet, J. (BioMed Central, 2020)
    Abstract Background The analysis of mobile health (mHealth) data has generated innovative insights into improving allergic rhinitis control, but additive information is needed. A cross-sectional real-world observational study was undertaken in 17 European countries during and outside the estimated pollen season. The aim was to collect novel information including the phenotypic characteristics of the users. Methods The Allergy Diary–MASK-air–mobile phone app, freely available via Google Play and App, was used to collect the data of daily visual analogue scales (VASs) for overall allergic symptoms and medication use. Fluticasone Furoate (FF), Mometasone Furoate (MF), Azelastine Fluticasone Proprionate combination (MPAzeFlu) and eight oral H1-antihistamines were studied. Phenotypic characteristics were recorded at entry. The ARIA severity score was derived from entry data. This was an a priori planned analysis. Results 9037 users filled in 70,286 days of VAS in 2016, 2017 and 2018. The ARIA severity score was lower outside than during the pollen season. Severity was similar for all treatment groups during the pollen season, and lower in the MPAzeFlu group outside the pollen season. Days with MPAzeFlu had lower VAS levels and a higher frequency of monotherapy than the other treatments during the season. Outside the season, days with MPAzeFlu also had a higher frequency of monotherapy. The number of reported days was significantly higher with MPAzeFlu during and outside the season than with MF, FF or oral H1-antihistamines. Conclusions This study shows that the overall efficacy of treatments is similar during and outside the pollen season and indicates that medications are similarly effective during the year.
  • MASK Study Grp; Bedard, A.; Basagana, X.; Anto, J. M.; Haahtela, T.; Toppila-Salmi, S.; Valovirta, E.; Bousquet, J. (2020)
    Background The analysis of mobile health (mHealth) data has generated innovative insights into improving allergic rhinitis control, but additive information is needed. A cross-sectional real-world observational study was undertaken in 17 European countries during and outside the estimated pollen season. The aim was to collect novel information including the phenotypic characteristics of the users. Methods The Allergy Diary-MASK-air-mobile phone app, freely available via Google Play and App, was used to collect the data of daily visual analogue scales (VASs) for overall allergic symptoms and medication use. Fluticasone Furoate (FF), Mometasone Furoate (MF), Azelastine Fluticasone Proprionate combination (MPAzeFlu) and eight oral H1-antihistamines were studied. Phenotypic characteristics were recorded at entry. The ARIA severity score was derived from entry data. This was an a priori planned analysis. Results 9037 users filled in 70,286 days of VAS in 2016, 2017 and 2018. The ARIA severity score was lower outside than during the pollen season. Severity was similar for all treatment groups during the pollen season, and lower in the MPAzeFlu group outside the pollen season. Days with MPAzeFlu had lower VAS levels and a higher frequency of monotherapy than the other treatments during the season. Outside the season, days with MPAzeFlu also had a higher frequency of monotherapy. The number of reported days was significantly higher with MPAzeFlu during and outside the season than with MF, FF or oral H1-antihistamines. Conclusions This study shows that the overall efficacy of treatments is similar during and outside the pollen season and indicates that medications are similarly effective during the year.